Oxaprozin Dose Proportionality
- 12 November 1984
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 24 (11) , 515-522
- https://doi.org/10.1002/j.1552-4604.1984.tb02761.x
Abstract
Twelve normal subjects each received single 300‐, 600‐, and 1200‐mg oral doses of oxaprozin according to a three‐period crossover design. Total drug plasma concentrations did not increase in proportion to the dose administered. Total clearance (Clo) and volume of distribution (Vd) increased with dose, though elimination t1 2 remained unchanged. The fraction of unbound oxaprozin in plasma (fup) varied linearly with total plasma concentration: it increased from 0.068 per cent at 10 μg/ml to 0.180 per cent at 170 μg/ml. A parameter f̂up was therefore introduced to express the average degree of unbound drug plasma for a given dose, and to allow the calculation of unbound volume of distribution (Vdu) and intrinsic clearance (Cli) as if binding were constant. Even though f̂up increased with dose, the overall binding in the body (f̂ub ∼0.52 per cent) was relatively stable. Neither Vdu nor Cli changed with dose; hence, unbound oxaprozin kinetics can be considered to be linear. Protein binding had no effect on unbound oxaprozin plasma levels within the given dose range, and there was a one‐to‐one proportionality between the dose administered and the unbound drug concentration in plasma.This publication has 22 references indexed in Scilit:
- Effects of Oxaprozin Alone or in Combination with Aspirin on Hemostasis and Plasma Protein BindingThe Journal of Clinical Pharmacology, 1983
- Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agentInflammation Research, 1982
- Distribution Volume Related to Body Weight and Protein BindingJournal of Pharmaceutical Sciences, 1982
- Effect of saturable binding on the pharmacokinetics of drugs: a simulationJournal of Pharmacy and Pharmacology, 1980
- Macro- and Micromethods for High-Performance Liquid Chromatographic Analysis of Oxaprozin in PlasmaJournal of Pharmaceutical Sciences, 1980
- Original ArticleClinical Pharmacokinetics, 1979
- Clinical Pharmacokinetics of PhenylbutazoneClinical Pharmacokinetics, 1978
- SHAM, a method for biexpone ial carve resolution using initial slope, height, area and moment of the experimental decay type curveJournal of Theoretical Biology, 1975
- Anti-inflammatory properties of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin)Inflammation Research, 1974
- FACTORS AFFECTING DRUG METABOLISMAnnals of the New York Academy of Sciences, 1971